Teva Pharmaceuticals Industries' (TEVA) US affiliate, Teva Pharmaceuticals, said Monday that its biosimilar Epysqli, developed in collaboration with Samsung Bioepis, is now available in the US to treat rare conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
Epysqli was approved by the US Food and Drug Administration last year, and it will be priced 30% below Soliris, the brand-name equivalent, Teva said.
The FDA has provisionally determined that Epysqli will be interchangeable with Soliris once the first interchangeable biosimilar's exclusivity period expires, the company said.
Shares of the company were up more than 4% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.